Compare DexCom, Inc. (DXCM) vs Herbalife Nutrition Ltd (HLF) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

HLF trades at $12.45, up 1.72% today, with a bearish technical signal from moving averages. The company shows stable revenue around $5B annually, with a net income margin of 4.66% in 2025. Recent Q1 2026 earnings beat expectations, and the company raised full-year guidance. Positive news includes inclusion in TIME's America's Best Companies 2026 and a major debt refinancing, though insider selling and negative shareholder equity present concerns.

The outlook is mixed: strong brand recognition and earnings beats support upside, but high debt levels and bearish technicals pose risks. Analyst consensus is bullish with 57.7% buy ratings, yet the stock faces headwinds from competitive pressures and reliance on international growth markets like India.